

PHARMACEUTICAL 2023

Amneal Pharmaceuticals Inc. Rank 297 of 446









PHARMACEUTICAL 2023



Amneal Pharmaceuticals Inc. Rank 297 of 446

The relative strengths and weaknesses of Amneal Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Amneal Pharmaceuticals Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 75% points. The greatest weakness of Amneal Pharmaceuticals Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 164% points.

The company's Economic Capital Ratio, given in the ranking table, is 5.0%, being 38% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	1,411,818
Cost of Goods Sold	1,416,485
Intangible Assets	1,694,946
Liabilities, Current	752,800
Liabilities, Non-Current	2,837,613
Other Assets	222,762
Other Compr. Net Income	159,679
Other Expenses	35,320
Other Liabilities	0
Other Net Income	-419,900
Other Revenues	2,212,304
Property and Equipment	469,815
Research and Development	195,688
Selling, General and Administrative Expense	399,700

Output Variable	Value in 1000 USD
Assets	3,799,341
Liabilities	3,590,413
Expenses	2,047,193
Revenues	2,212,304
Stockholders Equity	208,928
Net Income	-254,789
Comprehensive Net Income	-174,950
Economic Capital Ratio	5.0%

